Alber Burgess-Hull

Albert Burgess-Hull, PhD is the Scientific Director at SUDx. Dr. Burgess-Hull and his research team have developed a real-time risk-stratification tool that predicts a patient's response to medication for opioid use disorder (MOUD) early in treatment. MOUD is a first-line treatment for opioid use disorder, but not all patients respond the same way. Currently, there’s no reliable way to predict which patients will be resistant to treatment, leading to delays in optimal care and potential disparities in access to quality treatment. Their system uses a model that forecasts substance use and medication adherence patterns, adjusts buprenorphine dosages, and flags improper use, helping clinicians provide personalized and timely care. This framework has broad potential beyond opioid use disorder, as it can be applied to other substance use disorders and chronic health conditions that require ongoing monitoring.